We are live on ! Find out more
MBII

Marrone Bio Innovations, Inc.

Delisted

MBII was delisted on the 12th of July, 2022.

40 hedge funds and large institutions have $96.7M invested in Marrone Bio Innovations, Inc. in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 18 increasing their positions, 9 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 9

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

8% more funds holding

Funds holding: 3740 (+3)

7% more capital invested

Capital invested by funds: $90.5M → $96.7M (+$6.28M)

Holders
40
Holders Change
+3
Holders Change %
+8.11%
% of All Funds
1.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
18
Reduced
9
Closed
5
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
GGHC
1
Gilder Gagnon Howe & Co
New York
$18.8M +$2.01M +123,734 +13%
WRF
2
Waddell & Reed Financial
Kansas
$18.3M +$471K +29,000 +3%
Massachusetts Financial Services
3
Massachusetts Financial Services
Massachusetts
$11.9M -$3.73M -229,690 -26%
PWAM
4
Park West Asset Management
California
$9.75M -$776K -47,774 -8%
Capital Research Global Investors
5
Capital Research Global Investors
California
$8M
Primecap Management
6
Primecap Management
California
$7.1M -$583K -35,900 -8%
KCM
7
Kornitzer Capital Management
Kansas
$5.38M +$1.57M +96,650 +47%
Alyeska Investment Group
8
Alyeska Investment Group
Illinois
$3.67M +$129K +7,918 +4%
BFA
9
BlackRock Fund Advisors
California
$2.61M -$99.4K -6,117 -4%
Principal Financial Group
10
Principal Financial Group
Iowa
$2.21M +$26K +1,600 +1%
Vanguard Group
11
Vanguard Group
Pennsylvania
$1.59M +$926K +56,981 +177%
Northern Trust
12
Northern Trust
Illinois
$1.08M +$646K +39,739 +192%
Deutsche Bank
13
Deutsche Bank
Germany
$988K +$407K +25,034 +82%
AAP
14
Ardsley Advisory Partners
Connecticut
$889K
State Street
15
State Street
Massachusetts
$804K +$164K +10,124 +29%
BIT
16
BlackRock Institutional Trust
California
$757K +$311K +19,147 +82%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$535K +$30.6K +1,886 +7%
Millennium Management
18
Millennium Management
New York
$445K -$169K -10,400 -29%
EEG
19
E.E. Geduld
$356K +$325K +20,000 New
Bank of New York Mellon
20
Bank of New York Mellon
New York
$332K +$135K +8,284 +80%
BIM
21
BlackRock Investment Management
Delaware
$282K +$53.7K +3,304 +26%
TCIM
22
TIAA CREF Investment Management
New York
$232K +$43.7K +2,690 +26%
California State Teachers Retirement System (CalSTRS)
23
California State Teachers Retirement System (CalSTRS)
California
$174K +$32.5K +2,000 +26%
RFS
24
Rockefeller Financial Services
New York
$143K +$131K +8,053 New
TA
25
Teachers Advisors
New York
$91K

MBII Hedge Fund Activity: Q4 2013 in Review

40 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Marrone Bio Innovations, Inc. (MBII) for Q4 2013, worth a combined $96.7M — up 6.9% from $90.5M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new MBII positions and 5 closed out — a net gain of 3 holders — while 18 added to existing stakes and 9 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $2.01M. The largest seller was Massachusetts Financial Services, cutting an estimated $3.73M.

  • 40 institutional investors held Marrone Bio Innovations, Inc. (MBII) as of Q4 2013, up from 37 in Q3 2013.
  • Funds reported $96.7M of Marrone Bio Innovations, Inc. stock for Q4 2013, up 6.9% quarter-over-quarter.
  • 8 funds opened new Marrone Bio Innovations, Inc. positions in Q4 2013 and 5 closed out, a net change of +3 holders.
  • The largest Marrone Bio Innovations, Inc. buyer in Q4 2013 was Gilder Gagnon Howe & Co, an estimated $2.01M added.
  • The largest Marrone Bio Innovations, Inc. seller in Q4 2013 was Massachusetts Financial Services, an estimated $3.73M sold.

Based on aggregated 13F filings for Q4 2013.